ArticleMedComm2025

First-Line Third-Generation EGFR Tyrosine Kinase Inhibitor Monotherapy for Advanced EGFR-Mutated Non-Small Cell Lung Cancer: A Systematic Review and Network Meta-Analysis.

Wei Du et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.